TGN-020

TGN-020 is a selective Aquaporin 4 (AQP4) inhibitor with an IC50 of 3.1 μM[1][2]. TGN-020 is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[3].TGN-020 alleviates edema and inhibits glial scar formation after spinal cord compression injury in rats[4].

Product Specifications

CAS Number

[51987-99-6]

UNSPSC

12352005

Hazard Statement

H302

Target

PROTAC Linkers

Type

Reference compound

Related Pathways

PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tgn-020.html

Purity

99.97

Solubility

DMSO : 16.67 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=CN=C1)NC2=NN=CS2

Molecular Formula

C8H6N4OS

Molecular Weight

206.23

Precautions

H302

References & Citations

[1]An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562|[2]Vincent J Huber, et al. Identification of aquaporin 4 inhibitors using in vitro and in silico methods. Bioorg Med Chem. 2009 Jan 1;17 (1) :411-7.|[3]Shou Oosuka, et al. Effects of an Aquaporin 4 Inhibitor, TGN-020, on Murine Diabetic Retina. Int J Mol Sci. 2020 Mar 27;21 (7) :2324.|[4]Jian Li, et al. TGN-020 alleviates edema and inhibits astrocyte activation and glial scar formation after spinal cord compression injury in rats. Life Sci. 2019 Apr 1;222:148-157.